Sign in
CompletedNo phase

An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders

Key facts

Who runs it
Lupin Ltd.
Where
France, Germany, and United Kingdom6 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
53 people enrolled
Started
17 Dec 2020
Ended
16 Jan 2026
Type of study
Observational
Treatments tested
  • Mexiletine
Record updated
22 June 2026

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adult, male or female patients with non-dystrophic myotonic disorders planned to be started on Namuscla according to the approved SmPC
  • Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients on mexiletine other than Namuscla, only those who switch to Namuscla will be enrolled)
  • Patients who understand and are willing to provide informed consent

Who cannot take part

  • Patients who are enrolled or participating in any other clinical trial for an investigational product. -
  • Patients receiving drugs that can induce torsades de pointes
  • Patients receiving medicinal products with narrow therapeutic index (ie, theophylline, tizanidine, digoxin, lithium, phenytoin or warfarin)
  • Hypersensitivity to mexiletine, or to any of the excipients of Namuscla, or hypersensitivity to any local anaesthetic
  • Complete heart block (ie, third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
  • Myocardial infarction (acute or past), or abnormal Q-waves
  • Symptomatic coronary artery disease
  • Heart failure with reduced ejection fraction <50%
  • Ventricular tachyarrhythmia
  • Atrial tachyarrhythmia, fibrillation or flutter
  • Sinus node dysfunction (including sinus rate < 50 bpm)
  • Patients who are pregnant or lactating

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM.

Treatments tested

  • Mexiletine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients With Non-dystrophic Myotonic Disorders
Record updated
22 June 2026